ClinicalTrials.gg
Status unknownNCT04155554DOBINeuroUpdated Jan 31, 2020

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen

A Phase 3 interventional study of Bictegravir/emtricitabine/tenofovir alafenamide and Dolutegravir/lamivudine/abacavir in HIV-1-infection, sponsored by Azienda Ospedaliera Universitaria Senese. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-31.

Sponsored by Azienda Ospedaliera Universitaria Senese · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. The hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir.

Read the detailed description

Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. The hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir. The main outcome measure will be a global severity index (GSI) of neuropsychiatric symptoms arising from 10 symptom domains, including somatization, obsessive-compulsiveness, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism. The secondary outcomes are to compare, between arms and during follow up, neuropsychiatric symptoms severity, neurocognitive performance, changes in self-reported symptoms, adherence and HR-QoL, correlation between symptoms (neuropsychiatric and other), drug exposure and HR-QoL, proportion of adverse events, proportion of virological failures and antiretrovirals resistance at virological failure.

02

Conditions studied

  • HIV-1-infection

Keywords

  • HIV
  • Neurocognitive functions
  • Neuropsychiatric side effects
  • Bictegravir
  • INSTI
03

In context

Lead sponsor

Azienda Ospedaliera Universitaria Senese is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • -1 infection
  • HIV RNA \<50 copies/mL >12 months (including patients with 1 blip 50-200 cp/mL before screening, not confirmed)
  • On treatment with dolutegravir/abacavir/lamivudine >6 months

Exclusion criteria

Exclusion Criteria:

  • Previous AIDS events
  • Pregnancy or pregnancy plan
  • Decompensated cirrhosis (B or C CPT status)
  • Intake of alcohol, substances, other drugs that may affect neurocognitive performances
  • Necessity to receive drugs that may require dosing adjustment of dolutegravir or bictegravir
  • Certified diagnosis of major depression, psychosis, history of suicidal attempts
  • Treatment with antidepressants or antipsychotic drugs
  • History of virological failure with INSTIs
  • Lack of knowledge of italian language
  • Impossibility to obtain informed written consent
  • positivity
  • Estimated by CK-EPI \<50 mL/min per 1.73 m2
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Bictegravir/emtricitabine/tenofovir alafenamide

    Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD

    Drug: Bictegravir/emtricitabine/tenofovir alafenamide

  • Active comparator
    Dolutegravir/lamivudine/abacavir

    Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD

    Drug: Dolutegravir/lamivudine/abacavir

Interventions

06

What researchers measure

Primary outcomes

  1. neuropsychiatric symptoms severity in 3 months

    change in neuropsychiatric symptoms severity, using the Symptom Checklist-90-R, 3 months after switching to bictegravir or continuing dolutegravir (on treatment analysis).

    Time frame: 3 months

Secondary outcomes

  1. neuropsychiatric symptoms severity in 3 and 12 months

    change in neuropsychiatric symptoms severity, each of the 10 symptoms analyzed separately using the Symptom Checklist-90-R, 3 and 12 months after switching to bictegravir or dolutegravir (on treatment analysis)

    Time frame: 12 months

  2. Mini International Neuropsychiatric Interview Plus subscale for suicide risk

    change in neuropsychiatric symptoms severity, using the Mini International Neuropsychiatric Interview Plus subscale for suicide risk, 3 and 12 months after switching to bictegravir or dolutegravir (on treatment analysis). Suicide risk (five questions, score range 0-33 points) in the last 30 days was classified as low (1-5), moderate (6-9), or high (10).

    Time frame: 12 months

  3. neurocognitive performance

    change in neurocognitive performance, using a comprehensive and validated neuropsychological battery, 12 months after switching to bictegravir or dolutegravir (on treatment analysis). The neurocognitive performance is calculated by averaging the individual deficit scores from each neurocognitive test. Deficit scores for each test were calculated from age-, education-, -adjusted raw scores.

    Time frame: 12 months

  4. neurocognitive impairment and neuropsychiatric symptoms

    comparison of the inter-arm and intra-arm incidence of neurocognitive impairment (on the basis of Frascati criteria) at 12 months and neuropsychiatric symptoms (using the Symptom Checklist-90-R) at 3 (on treatment analysis) and 12 months (ITT-exposed, using LOCF)

    Time frame: 12 months

  5. self-reported symptoms (21 items, 0-5 points for each), adherence (0-100%) and HR-QoL (9 items, 0-5 points for each)

    changes in self-reported symptoms, adherence and HR-QoL (using validated questionnaires) during the first year of follow up (ITT-exposed, using LOCF).

    Time frame: 12 months

  6. drug exposure

    correlation between symptoms (neuropsychiatric and other), drug exposure and HR-QoL during the first year of follow up (ITT-exposed, using LOCF).

    Time frame: 12 months

  7. adverse events

    proportion of adverse events and serious adverse events and of patients discontinuing due to side effects in both arms

    Time frame: 12 months

  8. virological failures

    proportion of virological failures and antiretrovirals resistance at virological failure

    Time frame: 12 months

  9. Treatment Satisfaction

    change in Treatment Satisfaction between arms as per specific questionnaire (TSQM Version 1.4, 15 questions, from 0 to 79 points as maximum)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Aug 2020, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 7, 2019
StartActual
Jan 29, 2020
Primary completionEst.
Aug 2020
CompletionEst.
Jul 2021
Last update
Jan 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04155554
Lead sponsor
Azienda Ospedaliera Universitaria Senese
Collaborators
Catholic University of the Sacred Heart, Ospedale Policlinico San Martino, Azienda Ospedaliera San Paolo, Ospedale Amedeo di Savoia
Responsible party
Barbara Rossetti (Principal Investigator, Azienda Ospedaliera Universitaria Senese) — Principal investigator
First posted
Nov 7, 2019
Start date
Jan 29, 2020
Primary completion
Aug 2020 (estimated)
Completion
Jul 2021 (estimated)
Last update
Jan 31, 2020

Study contacts

Barbara Rossetti, PhD
Contact
barbara.rossetti@ao-siena.toscana.it
+393201437658
Maurizio Zazzi, Prof
Contact
maurizio.zazzi@unisi.it
+390577233863
Barbara Rossetti, PhD
principal investigator · Azienda Ospedaliera Universitaria Senese

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion